CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma

First patient administered in dose-confirmation Part B of Phase 1 study with mRNA-based, multiepitope cancer vaccine candidate CVGBM

15-Aug-2024 - CureVac N.V.announced the start of the dose-confirmation Part B of its ongoing Phase 1 study in patients with resected glioblastoma. CVGBM is CureVac’s first investigational cancer vaccine based on its proprietary second-generation mRNA backbone. It encodes a single fusion protein comprising ...

Novel compound for targeted tumor therapy in patients with soft tissue sarcoma

Thermosome Receives Regulatory Approval for First-In-Human Trial with its Lead Program THE001

04-Apr-2023 - Thermosome announced that it has received approval from the German Federal Institute for Drugs and Medical Devices (BfArM) and the responsible Ethics Committee to conduct a Phase 1 trial with its lead program THE001 in Germany. Patient enrollment is expected to start in Q2, 2023. The primary ...

CureVac Receives Regulatory Approval to Initiate Phase 1 Clinical Trial of its SARS-CoV-2 Vaccine Candidate

Trial will start promptly and will be conducted in Germany and Belgium

18-Jun-2020 - CureVac AG announced that the German Health Authority Paul-Ehrlich-Institute (PEI) and the Belgian Federal Agency for Medicines and Health Products (FAMHP) have approved the Phase 1 clinical trial for its vaccine program to prevent SARS-CoV-2 infection. The trial will be conducted in Germany and ...

CureVac enters clinical phase with mRNA vaccine

First data expected on intramuscular application of the newly developed vaccine

25-Oct-2018 - CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, today announced the initiation of its Phase I dose-escalation clinical trial with the novel mRNA-based rabies vaccine, CV7202. This is the first-in-human clinical trial of CureVac’s naturally ...

Galapagos and MorphoSys announce start of a Phase 1 subcutaneous bridging study with MOR106

17-Sep-2018 - Galapagos NV and MorphoSys AG announced the initiation of a Phase 1 bridging study testing a subcutaneous formulation of MOR106, an investigational antibody directed against IL-17C. This bridging study is a parallel-design Phase 1 clinical trial conducted in two parts. Part 1 is a single center, ...

Ablynx to receive milestone for bi-specific nanobody in oncology

01-Feb-2016 - Ablynx announced that Boehringer Ingelheim has administered the first dose in a Phase I dose escalation study with the half-life extended bi-specific anti-VEGF/Ang2 Nanobody® in adult patients with advanced solid tumors, triggering an €8 million milestone payment to Ablynx. The aim of the study ...

First-in-class investigational therapeutic shows early promise for lymphoma patients

11-Nov-2015 - Results from a phase I clinical trial showed that the first-in-class, investigational, anticancer therapeutic pevonedistat was safe, tolerable, and had some anticancer activity in heavily pretreated patients with relapsed/refractory lymphoma. The study was published in Clinical Cancer ...

Investigational KW-0761 efficiently depletes immune system-suppressing Treg cells

02-Oct-2015 - In a phase Ia clinical trial, immune cells called Tregs, which can inhibit anticancer immune responses, were efficiently eliminated from the blood of patients with lung or esophageal cancer by treatment with the investigational therapeutic antibody KW-0761. Author(s): Ryuzo Ueda, MD, PhD, ...

Sanofi and Regeneron Launch Major New Immuno-Oncology Collaboration

Companies agree to jointly advance PD-1 and other new immuno-oncology antibodies

29-Jul-2015 - Sanofi and Regeneron Pharmaceuticals, Inc. have entered into a new global collaboration to discover, develop and commercialize new antibody cancer treatments in the emerging field of immuno-oncology. As part of the agreement, the two companies will jointly develop a programmed cell death protein ...

MGB Biopharma commences Phase I clinical trial with oral formulation of MGB-BP-3 for treatment of multi-resistant Clostridium Difficile infections

23-Jul-2015 - MGB Biopharma announced that the first group of healthy male volunteers have been dosed in a Phase I clinical trial assessing the safety and tolerability of an oral formulation of MGB-BP-3, for use in the treatment of Clostridium difficile infections.MGB-BP-3 is an antibiotic that has been shown ...